Cycloserine
ApprovedSmall molecule
Cycloserine is one of 167 small molecule programs targeting Smoking Behavior. It is currently in Approved.
7
Indications
13
Total Trials
2
Active Trials
166
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
297 competitors in Tuberculosis
#DrugCompanyPhaseTrials
1Zyvox
PfizerPhase 3
Levaquin
WWim Janssens
Phase 3
Cycloserine
UUniversity of Calgary
Approved
Deltavit
HHyundai Pharmaceutical Co., LTD.
Phase 3
Rayos
RRoxane Laboratories
Phase 3
Intensified TBM Treatment
AANRS, Emerging Infectious Diseases
Phase 3
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Preclinical
Tivicay
GSKPreclinical
Biktarvy
GileadPreclinical
Vemlidy
GileadPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cycloserine3 trials
Tuberculosis1 trial
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
Active, not recruiting·—·Phase 3·NCT06081361·186 enrolled
6 more indications
Smoking Cessation1 trial
Investigation of Cycloserine as a Smoking Cessation Treatment
Completed·—·Phase 1·NCT01062932·34 enrolled
RR-TB1 trial
Pulmonary Tuberculosis1 trial
A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.
Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000796·525 enrolled
Multidrug-Resistant Tuberculosis1 trial
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
Unknown status·—·Phase 4·NCT05306223·212 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Cycloserine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Calgary